Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 21
Filter
2.
Diabetes Metab ; 44(3): 217-225, 2018 Jun.
Article in English | MEDLINE | ID: mdl-29257747

ABSTRACT

Primary prevention aims to avert the onset of cardiovascular disease (CVD) by targeting its natural causes and risk factors; secondary prevention includes strategies and therapies that address preclinical or clinical evidence of CVD progression. The value of aspirin for primary CVD prevention is controversial because of increased bleeding, which may offset the overall modest benefits in patients with no overt CVD. In contrast, the benefits of aspirin for secondary prevention have been repeatedly and convincingly demonstrated to outweigh the risk of bleeding. Diabetes mellitus is a strong risk factor for cardiovascular events, and has been associated with an increased risk of both first and recurrent atherothrombotic events. Therefore, prevention of CVD, the major cause of mortality in patients with diabetes, is one of the most important therapeutic goals. Although the benefit of low-dose aspirin for secondary prevention of CVD is well established, its role for primary prevention remains inconclusive and controversial in diabetes patients. The benefit of aspirin for patients with CVD clearly exceeds the risk of bleeding, and even though a modest benefit has also been demonstrated in primary prevention, the trade-off for aspirin initiation against the increased risk of intracranial and gastrointestinal bleeding is more uncertain. Thus, aspirin for primary CVD prevention should be highly individualized, based on a benefit-risk ratio assessment for the given patient. In conclusion, the mere presence of diabetes is apparently not enough for aspirin to confer a benefit that clearly outweighs the risk of bleeding, and further evidence to the contrary is now needed.


Subject(s)
Aspirin/administration & dosage , Cardiovascular Diseases/prevention & control , Diabetes Complications/prevention & control , Fibrinolytic Agents/administration & dosage , Aspirin/therapeutic use , Fibrinolytic Agents/therapeutic use , Humans , Primary Prevention , Risk Factors
3.
Neurosurg Rev ; 37(1): 1-14, 2014 Jan.
Article in English | MEDLINE | ID: mdl-24306170

ABSTRACT

Unruptured intracranial aneurysms represent a decisional challenge. Treatment risks have to be balanced against an unknown probability of rupture. A better understanding of the physiopathology is the basis for a better prediction of the natural history of an individual patient. Knowledge about the possible determining factors arises from a careful comparison between ruptured versus unruptured aneurysms and from the prospective observation and analysis of unbiased series with untreated, unruptured aneurysms. The key point is the correct identification of the determining variables for the fate of a specific aneurysm in a given individual. Thus, the increased knowledge of mechanisms of formation and eventual rupture of aneurysms should provide significant clues to the identification of rupture-prone aneurysms. Factors like structural vessel wall defects, local hemodynamic stress determined also by peculiar geometric configurations, and inflammation as trigger of a wall remodeling are crucial. In this sense the study of genetic modifiers of inflammatory responses together with the computational study of the vessel tree might contribute to identify aneurysms prone to rupture. The aim of this article is to underline the value of a unifying hypothesis that merges the role of geometry, with that of hemodynamics and of genetics as concerns vessel wall structure and inflammatory pathways.


Subject(s)
Aneurysm, Ruptured/etiology , Aneurysm/etiology , Intracranial Aneurysm/etiology , Aneurysm/genetics , Aneurysm/pathology , Aneurysm, Ruptured/genetics , Aneurysm, Ruptured/pathology , Environment , Hemodynamics , Humans , Intracranial Aneurysm/genetics , Intracranial Aneurysm/pathology , Risk Factors
4.
Br J Pharmacol ; 151(7): 1087-94, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17592518

ABSTRACT

BACKGROUND AND PURPOSE: Electrophysiological studies described potentiation of NMDA receptor function by metabotropic glutamate receptors (mGluRs) of group I occurring postsynaptically. Since release-enhancing NMDA receptors exist on noradrenergic terminals and group I mGluRs have recently been identified on these nerve endings, we have investigated if NMDA receptor-mGluR interactions also can occur at the presynaptic level. EXPERIMENTAL APPROACH: Rat hippocampus and human neocortex synaptosomes were labelled with [(3)H]noradrenaline and superfused with mGluR agonists and antagonists. NMDA-evoked [(3)H]noradrenaline release was produced by removal of external Mg(2+) or by simultaneous application of NMDA and AMPA in Mg(2+)-containing solutions. KEY RESULTS: The mGluR1/5 agonist 3,5-DHPG, inactive on its own, potentiated both the release of [(3)H]noradrenaline elicited by AMPA/NMDA/glycine and that evoked by NMDA/glycine following Mg(2+) removal. The effect of 3,5-DHPG on the AMPA/NMDA/glycine-induced release was insensitive to the mGluR1 antagonist CPCCOEt, but it was abolished by the mGluR5 antagonist MPEP; moreover, it was potentiated by the mGluR5 positive allosteric modulator DFB. When NMDA receptors were activated by Mg(2+) removal, both mGluR5 and mGluR1 contributed to the evoked release, the mGluR-mediated release being blocked only by CPCCOEt and MPEP in combination. Experiments with human neocortex synaptosomes show NMDA receptor-mGluR interactions qualitatively similar to those observed in rodents. CONCLUSIONS AND IMPLICATIONS: Group I mGluRs, both of the mGluR1 and mGluR5 subtypes, co-localize with NMDA receptors on noradrenergic terminals of rat hippocampus and human neocortex. Depending on the mode of activation, NMDA receptors exert differential permissive roles on the activation of presynaptic mGluR1 and mGluR5.


Subject(s)
Presynaptic Terminals/physiology , Receptor Cross-Talk/physiology , Receptors, N-Methyl-D-Aspartate/physiology , Receptors, Presynaptic/physiology , Animals , Cerebral Cortex/drug effects , Cerebral Cortex/metabolism , Cerebral Cortex/physiology , Chromones/pharmacology , Female , Glycine/analogs & derivatives , Glycine/pharmacology , Hippocampus/drug effects , Hippocampus/metabolism , Hippocampus/physiology , Humans , Male , N-Methylaspartate/pharmacology , Norepinephrine/metabolism , Norepinephrine/pharmacology , Presynaptic Terminals/drug effects , Presynaptic Terminals/metabolism , Protein Binding/drug effects , Rats , Rats, Sprague-Dawley , Receptor Cross-Talk/drug effects , Receptor, Metabotropic Glutamate 5 , Receptors, AMPA/metabolism , Receptors, AMPA/physiology , Receptors, Metabotropic Glutamate/metabolism , Receptors, Metabotropic Glutamate/physiology , Receptors, N-Methyl-D-Aspartate/metabolism , Receptors, Presynaptic/metabolism , Resorcinols/pharmacology , Synaptosomes/drug effects , Synaptosomes/metabolism , Synaptosomes/physiology , Tritium , alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid/pharmacology
5.
Blood Coagul Fibrinolysis ; 10(8): 459-63, 1999 Dec.
Article in English | MEDLINE | ID: mdl-10636456

ABSTRACT

The role of blood tests in identifying patients at high risk for post-operative venous thromboembolism is undefined. The aim of this study was to evaluate the correlation between pre-operative plasma levels of soluble fibrin polymers (SFP), as determined by a recently developed enzyme-linked immunosorbent assay (ELISA) assay (TpP), and the incidence of deep vein thrombosis (DVT) after elective neurosurgery. Blood samples for SFP assay were withdrawn on the day before surgery from 157 consecutive patients undergoing elective neurosurgery for brain or spinal tumour. Patients were randomized to subcutaneous enoxaparin (40 mg once daily) or placebo given for at least 7 days. All patients wore compression stockings. DVT was assessed by bilateral venography, performed on day 8 +/- 1. Thirty-four patients (21.7%) were found to have a DVT, proximal in 11 (7%) and isolated distal in 23. Patients with and without DVT had a plasma pre-operative SFP levels of 6.2 +/- 4.6 and 1.9 +/- 1.5 mg/ml respectively (mean +/- SD) (P < 0.001). SFP levels in patients with proximal and isolated distal DVT were 7.6 +/- 5.1 and 5.5 +/- 4.4 microg/ml, respectively (P = 0.22). SFP cut-off levels categorized patients into three classes of DVT incidence. The incidence of DVT was 7.4% (6 of 81) for SFP levels < 2 microg/ml, 20.4% (11 of 54) for levels between 2 and 4.5 microg/ml, and 77.3% (17 of 22) for levels > 4.5 microg/ml (P= 0.001, Cochran-Mantel-Haenszel test). We conclude that pre-operative SFP levels correlate with post-operative DVT in elective neurosurgery patients. Further studies are required to define whether pre-operative SFP measurement could be useful in patient management.


Subject(s)
Elective Surgical Procedures/adverse effects , Fibrin/adverse effects , Neurosurgical Procedures/adverse effects , Venous Thrombosis/blood , Venous Thrombosis/etiology , Adult , Aged , Biomarkers/blood , Brain Neoplasms/complications , Brain Neoplasms/surgery , Enoxaparin/therapeutic use , Female , Humans , Italy/epidemiology , Male , Middle Aged , Risk Factors , Solubility , Spinal Neoplasms/complications , Spinal Neoplasms/surgery , Venous Thrombosis/drug therapy
6.
N Engl J Med ; 339(2): 80-5, 1998 Jul 09.
Article in English | MEDLINE | ID: mdl-9654538

ABSTRACT

BACKGROUND: Compression stockings are recommended for prophylaxis against venous thromboembolism in patients undergoing neurosurgery, but anticoagulant agents have not gained wide acceptance because of concern about intracranial bleeding. METHODS: In a multicenter, randomized, double-blind trial, we assessed the efficacy and safety of enoxaparin in conjunction with the use of compression stockings in the prevention of venous thromboembolism in patients undergoing elective neurosurgery. Enoxaparin (40 mg once daily) or placebo was given subcutaneously for not less than seven days beginning within 24 hours after the completion of surgery. The primary end point was symptomatic, objectively confirmed venous thromboembolism or deep-vein thrombosis assessed by bilateral venography, which was performed in all patients on day 8+/-1. Bleeding side effects were carefully assessed. RESULTS: Among the 307 patients assigned to treatment groups, 129 of the 154 patients receiving placebo (84 percent) and 130 of the 153 patients receiving enoxaparin (85 percent) had venographic studies adequate for analysis. An additional patient in the placebo group died before venography of autopsy-confirmed pulmonary embolism. In this analysis, 42 patients given placebo (32 percent) and 22 patients given enoxaparin (17 percent) had deep-vein thrombosis (relative risk in the enoxaparin group, 0.52; 95 percent confidence interval, 0.33 to 0.82; P=0.004). The rates of proximal deep-vein thrombosis were 13 percent in patients receiving placebo and 5 percent in patients receiving enoxaparin (relative risk in the enoxaparin group, 0.41; 95 percent confidence interval, 0.17 to 0.95; P=0.04). Two patients in the placebo group died of autopsy-confirmed pulmonary embolism on days 9 and 16. Major bleeding occurred in four patients receiving placebo (intracranial bleeding in all four) and four patients (intracranial bleeding in three) receiving enoxaparin (3 percent of each group). CONCLUSIONS: Enoxaparin combined with compression stockings is more effective than compression stockings alone for the prevention of venous thromboembolism after elective neurosurgery and does not cause excessive bleeding.


Subject(s)
Anticoagulants/therapeutic use , Bandages , Enoxaparin/therapeutic use , Neurosurgery , Postoperative Complications/prevention & control , Thromboembolism/prevention & control , Adult , Aged , Combined Modality Therapy , Double-Blind Method , Elective Surgical Procedures , Female , Humans , Male , Middle Aged , Postoperative Complications/epidemiology , Postoperative Complications/mortality , Pulmonary Embolism/mortality , Pulmonary Embolism/prevention & control , Thromboembolism/epidemiology , Thrombophlebitis/prevention & control
7.
Br J Pharmacol ; 120(1): 60-4, 1997 Jan.
Article in English | MEDLINE | ID: mdl-9117099

ABSTRACT

1. The release of endogenous gamma-aminobutyric acid (GABA) and glutamic acid in the human brain has been investigated in synaptosomal preparations from fresh neocortical samples obtained from patients undergoing neurosurgery to reach deeply located tumours. 2. The basal outflows of GABA and glutamate from superfused synaptosomes were largely increased during depolarization with 15 mM KCl. The K(+)-evoked overflows of both amino acids were almost totally dependent on the presence of Ca(2+) in the superfusion medium. 3. The GABAB receptor agonist (-)-baclofen (1, 3 or 10 microM) inhibited the overflows of GABA and glutamate in a concentration-dependent manner. The inhibition caused by 10 microM of the agonist ranged from 45-50%. 5. The effect of three selective GABAB receptor antagonists on the inhibition of the K(+)-evoked GABA and glutamate overflows elicited by 10 microM (-)-baclofen was investigated. Phaclofen antagonized (by about 50% at 100 microM; almost totally at 300 microM) the effect of (-)-baclofen on GABA overflow but did not modify the inhibition of glutamate release. The effect of (-)-baclofen on the K(+)-evoked GABA overflow was unaffected by 3-amino-propyl (diethoxymethyl)phosphinic acid (CGP 35348; 10 or 100 microM); however, CGP 35348 (10 or 100 microM) antagonized (-)-baclofen (complete blockade at 100 microM) at the heteroreceptors on glutamatergic terminals. Finally, [3-[[(3,4-dichlorophenyl) methyl]amino]propyl] (diethoxymethyl) phosphinic aid (CGP 52432), 1 microM, blocked the GABAB autoreceptor, but was ineffective at the heteroreceptors. The selectivity of CGP 52423 was lost at 30 microM, as the compound, at this concentration, inhibited completely the (-)-baclofen effect on both GABA and glutamate release. 5. It is concluded that GABA and glutamate release evoked by depolarization of human neocortex nerve terminals can be affected differentially through pharmacologically distinct GABAB receptors.


Subject(s)
Cerebral Cortex/metabolism , Glutamic Acid/metabolism , Receptors, GABA-B/metabolism , gamma-Aminobutyric Acid/metabolism , Aged , Amino Acids/metabolism , Baclofen/antagonists & inhibitors , Baclofen/pharmacology , Calcium/physiology , Cerebral Cortex/drug effects , Female , GABA Agonists/pharmacology , GABA-B Receptor Agonists , Humans , In Vitro Techniques , Male , Middle Aged , Potassium/pharmacology , Synaptosomes/drug effects , Synaptosomes/metabolism
8.
Br J Pharmacol ; 118(6): 1441-6, 1996 Jul.
Article in English | MEDLINE | ID: mdl-8832070

ABSTRACT

UNLABELLED: 1. The release of somatostatin-like immunoreactivity (SRIF-LI) in the human brain was studied in synaptosomal preparations from fresh neocortical specimens obtained from patients undergoing neurosurgery to remove deeply sited tumours. 2. The basal outflow of SRIF-LI from superfused synaptosomes was increased about 3 fold during exposure to a depolarizing medium containing 15 mM KCl. The K(+)-evoked overflow of SRIF-LI was almost totally dependent on the presence of Ca2+ in the superfusion medium. 3. The GABAB receptor agonist, (-)-baclofen (0.3 - 100 microM), inhibited the overflow of SRIF-LI in a concentration-dependent manner (EC50 = 1.84 +/- 0.20 microM; maximal effect: about 50%). The novel GABAB receptor ligand, 3-aminopropyl(difluoromethyl)phosphinic acid (CGP 47656) mimicked (-)-baclofen in inhibiting the SRIF-LI overflow (EC50 = 3.06 +/- 0.52 microM; maximal effect: about 50%), whereas the GABAA receptor agonist, muscimol, was ineffective up to 100 microM. 4. The inhibition by 10 microM (-)-baclofen of the K(+)-evoked SRIF-LI overflow was concentration-dependently prevented by two selective GABAB receptor antagonists, 3-amino-propyl (diethoxymethyl)-phosphinic acid (CGP 35348) (IC50 = 24.40 +/- 2.52 microM) and [3-[[(3,4-dichlorophenyl) methyl]amino]propyl] (diethoxymethyl) phosphinic acid (CGP 52432) (IC50 = 0.06 +/- 0.005 microM). 5. The inhibition of SRIF-LI overflow caused by 10 microM CGP 47656 was abolished by 1 microM CGP 52432. 6. When human synaptosomes were labelled with [3H]-GABA and depolarized in superfusion with 15 mM KCl, the inhibition by 10 microM (-)-baclofen of the depolarization-evoked [3H]-GABA overflow was largely prevented by 10 microM CGP 47656 which therefore behaved as an autoreceptor antagonist. 7. IN CONCLUSION: (a) the characteristics of SRIF-LI release from synaptosomal preparations of human neocortex are compatible with a neuronal origin; (b) the nerve terminals releasing the neuropeptide possess inhibitory receptors of the GABAB type; (c) these receptors differ pharmacologically from the GABAB autoreceptors present on human neocortex nerve terminals since the latter have been shown to be CGP 35348-insensitive but can be blocked by CGP 47656.


Subject(s)
Brain Chemistry/physiology , Cerebral Cortex/metabolism , Nerve Endings/metabolism , Receptors, GABA-B/metabolism , Somatostatin/metabolism , Adult , Aged , Brain Chemistry/drug effects , Calcium/physiology , Cerebral Cortex/drug effects , GABA Agonists/pharmacology , GABA-B Receptor Agonists , GABA-B Receptor Antagonists , Humans , In Vitro Techniques , Middle Aged , Nerve Endings/drug effects , Synaptosomes/metabolism
9.
AIDS ; 10(5): 463-8, 1996 May.
Article in English | MEDLINE | ID: mdl-8724036

ABSTRACT

OBJECTIVE: To investigate the effect of HIV-1 gp120 on the function of glutamate receptors of the N-methyl-D-aspartate (NMDA) type in the human brain. DESIGN: The monitoring of neurotransmitter release from superfused isolated nerve endings is widely recognized as a technique appropriate for the study of neurotransmitter release and to attribute a precise localization to the site(s) of action of drugs able to modulate release. METHODS: Synaptosomes (pinched-off nerve endings) were prepared from fresh human brain tissue samples removed during neurosurgery, labelled with [3H]-noradrenaline and superfused at a rate of 0.5 ml/min with NMDA in the presence of gp41, gp160, gp120 or the V3 loop, with or without NMDA receptor antagonists. Fractions of superfusate were collected and measured for radioactivity. RESULTS: NMDA elicited a glycine-sensitive release of [3H]-noradrenaline from human brain synaptosomes. HIV-1 gp120 potentiated the NMDA (1 mM)-evoked [3H]-noradrenaline release (maximal effect approximately 110% at 1 nM). The release elicited by NMDA plus gp120 was prevented by the classical NMDA receptor antagonists dizocilpine or 7-chlorokynurenic acid, as well as by memantine. The potentiation by gp120 of the NMDA-evoked [3H]-noradrenaline release was mimicked by gp160 but not by gp41. The effect of gp120 was retained by the V3 loop. Finally, gp120 reversed (1 nM) and surmounted (10nM) the antagonism by 10 microM 7-chlorokynurenate of the NMDA-evoked [3H]-noradrenaline release. CONCLUSION: gp 120 binds directly through the V3 loop at noradrenergic axon terminals in human brain neocortex and may alter the function of presynaptic NMDA receptors mediating regulation of noradrenaline release.


Subject(s)
Cerebral Cortex/metabolism , HIV Envelope Protein gp120/pharmacology , HIV-1 , Norepinephrine/metabolism , Receptors, N-Methyl-D-Aspartate/physiology , Adult , Aged , Allosteric Site , Excitatory Amino Acid Antagonists/pharmacology , Female , Gene Products, env/pharmacology , Glycine/metabolism , HIV Envelope Protein gp120/physiology , Humans , Kynurenic Acid/analogs & derivatives , Kynurenic Acid/pharmacology , Male , Middle Aged , N-Methylaspartate/pharmacology , Peptide Fragments/pharmacology , Peptide Fragments/physiology , Receptors, Glycine/antagonists & inhibitors , Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors , Receptors, N-Methyl-D-Aspartate/metabolism , Synaptosomes/metabolism
10.
Surg Neurol ; 42(6): 469-70, 1994 Dec.
Article in English | MEDLINE | ID: mdl-7825099

ABSTRACT

Pulmonary embolism (PE) is a severe complication in neurosurgery. The best treatment of PE is thrombolytic therapy, but the presence of either intracranial neoplasm or recent neurosurgical procedures is considered a major contraindication to this therapy. We have used urokinase thrombolytic therapy in nine of our patients with severe PE that occurred from 7 to 34 days after a neurosurgical operation. All patients survived. No intracranial hemorrhage occurred. We also advocate thrombolytic therapy for severe PE in patients who were recently operated on by neurosurgical procedure.


Subject(s)
Postoperative Complications/drug therapy , Pulmonary Embolism/drug therapy , Thrombolytic Therapy , Urokinase-Type Plasminogen Activator/therapeutic use , Adult , Aged , Craniotomy , Female , Humans , Laminectomy , Male , Middle Aged , Retrospective Studies , Treatment Outcome , Ventriculoperitoneal Shunt
11.
J Neurochem ; 63(3): 1163-6, 1994 Sep.
Article in English | MEDLINE | ID: mdl-8051559

ABSTRACT

Fenfluramine is the most widely used anorexigenic drug in humans. In animal experiments d-fenfluramine has been shown to act as a potent releaser of brain serotonin [5-hydroxytryptamine (5-HT)]. Here we have investigated the effects of d-fenfluramine on the release of [3H]5-HT from isolated nerve endings of human neocortex. The drug elicited release of unmetabolized [3H]5-HT, and this effect was concentration dependent. However, the mechanism of release seems to differ profoundly depending on the concentrations of d-fenfluramine used. At 5 microM, the release of [3H]5-HT was blocked by the 5-HT transporter inhibitor fluoxetine and was Ca2+ independent and insensitive to the human autoreceptor 5-HT1D agonist sumatriptan. The release of [3H]5-HT elicited by 0.5 microM d-fenfluramine was similarly blocked by fluoxetine, but it was strongly Ca2+ dependent and sensitive to sumatriptan. It is suggested that, at relatively high concentrations, d-fenfluramine largely diffuses into serotonergic terminals and causes release of 5-HT through the 5-HT carrier working in the inside-outside direction; at relatively low concentrations d-fenfluramine enters the terminals through the 5-HT transporter but elicits release of 5-HT by an exocytotic-like mechanism.


Subject(s)
Cerebral Cortex/metabolism , Fenfluramine/pharmacology , Nerve Endings/metabolism , Serotonin/metabolism , Calcium/pharmacology , Cerebral Cortex/drug effects , Fluoxetine/pharmacology , Humans , Nerve Endings/drug effects , Sumatriptan/pharmacology , Synaptosomes/metabolism , Tritium
12.
J Neurosurg Sci ; 38(3): 167-70, 1994 Sep.
Article in English | MEDLINE | ID: mdl-7782862

ABSTRACT

The authors report a case of tension intraventricular pneumocephalus developed six months after the removal of an acoustic neuroma and a CSF ventriculoperitoneal shunt procedure due to a concomitant hydrocephalus. A review of the literature show only 19 cases of CSF shunt complicating pneumocephalus. The authors discuss both about the etiology of pneumocephalus and its therapeutic options. In our case we were unable to preoperatively localize the cranial base communication allowing intracranial air antry. The literature show however that eroded or thinned bone areas may be multiple and even diffuse their development depending upon several factors. We suggest in these cases a direct surgical repair through a craniotomy, as reported by others, is not mandatory. According to the etiology of pneumocephalus a temporary extraventricular drainage and the revision of the shunting pressure regimen may represent an effective treatment of this complication.


Subject(s)
Cerebrospinal Fluid Shunts , Pneumocephalus/etiology , Postoperative Complications/etiology , Female , Follow-Up Studies , Frontal Lobe/diagnostic imaging , Humans , Hydrocephalus/surgery , Incidence , Magnetic Resonance Imaging , Middle Aged , Neuroma, Acoustic/surgery , Pneumocephalus/diagnostic imaging , Pneumocephalus/surgery , Postoperative Complications/diagnostic imaging , Postoperative Complications/surgery , Reoperation , Temporal Lobe/diagnostic imaging , Tomography, X-Ray Computed
14.
J Neurol Neurosurg Psychiatry ; 51(6): 796-802, 1988 Jun.
Article in English | MEDLINE | ID: mdl-2841428

ABSTRACT

Motor action potentials evoked by percutaneous electrical stimulation of the scalp and of the cervical (or lumbar) vertebral region were recorded from the biceps, thenar and tibialis anterior muscles in 30 patients with cervical spondylosis. Twelve normal controls were matched for age and height. Abnormalities of central motor conduction (absence or increased central delay of cortical responses) for at least one muscle were observed in all (but one) the patients with myelopathy alone or combined with radiculopathy. An increase in latency of the responses evoked by cervical stimulation occurred in 40% of patients with radiculopathy or myelo-radiculopathy. Changes of motor conduction occurred even in the absence of abnormalities of somatosensory evoked potentials, while the opposite was never observed. Direct stimulation of the motor tracts may be of value in the functional assessment of the motor pathways in cervical spondylosis.


Subject(s)
Cervical Vertebrae/physiopathology , Motor Neurons/physiology , Muscles/innervation , Spinal Osteophytosis/physiopathology , Synaptic Transmission , Adult , Aged , Electric Stimulation , Evoked Potentials, Somatosensory , Female , Humans , Male , Median Nerve/physiopathology , Middle Aged , Motor Cortex/physiopathology , Reaction Time/physiology , Spinal Cord/physiopathology , Spinal Nerve Roots/physiopathology
16.
Surg Neurol ; 26(6): 581-4, 1986 Dec.
Article in English | MEDLINE | ID: mdl-3490704

ABSTRACT

A patient harboring multiple hereditary exostoses with a long-lasting tetraparesis owing to intraspinal osteochondroma is described. The results of surgical treatment were poor in contrast to the results achieved by other previous authors performing decompression of the spinal cord. The related literature is briefly reviewed and conclusions are drawn in favor of computed tomographic examination of the spine of patients with vertebral complaints.


Subject(s)
Exostoses, Multiple Hereditary/complications , Spinal Cord Compression/etiology , Spinal Diseases/complications , Adult , Chondroma/complications , Humans , Male , Spinal Neoplasms/complications
18.
Riv Neurol ; 55(5): 332-7, 1985.
Article in Italian | MEDLINE | ID: mdl-4081540

ABSTRACT

The authors report a case of primary spinal hydatid cyst. A primary vertebral involvement occurs in about 1% of cases of Echinococcus granulosus infestations. In Italy only 23 cases have been reported to date. The diagnosis of spinal hydatidosis is often available only at the time of surgery because this disease has not specific characteristics as regards other more common causes of spinal cord compression. Surgery is mandatory but the wide bone infiltration makes difficult the radical excision and subsequently there is a high incidence of recurrences.


Subject(s)
Echinococcosis/pathology , Lumbar Vertebrae , Echinococcosis/complications , Echinococcosis/diagnosis , Epidural Space , Humans , Male , Middle Aged , Spinal Cord Compression/etiology , Spinal Diseases/complications , Spinal Diseases/diagnosis , Spinal Diseases/pathology
19.
J Neurol ; 232(5): 277-9, 1985.
Article in English | MEDLINE | ID: mdl-4056834

ABSTRACT

Forty-nine patients who suffered a spontaneous subarachnoid hemorrhage (SAH), and in whom panangiography did not show the cause of the bleeding, were evaluated after a long follow-up (median 8 years). No relationship was found between outcome and antifibrinolytic treatment or blood pressure level. Angiography was repeated in cases with spasm or after rebleeding: one aneurysm was found (7%). The authors suggest that angiography should be repeated in these circumstances. The early mortality was 2%. Late functional capacity was normal in 94% of the patients. No particular restrictions should therefore be recommended.


Subject(s)
Subarachnoid Hemorrhage/diagnosis , Adult , Aged , Aminocaproic Acid/adverse effects , Cerebral Angiography , Female , Follow-Up Studies , Humans , Hypertension/complications , Male , Middle Aged , Prognosis , Recurrence , Subarachnoid Hemorrhage/complications , Subarachnoid Hemorrhage/therapy
20.
J Neurooncol ; 3(3): 251-7, 1985.
Article in English | MEDLINE | ID: mdl-4056854

ABSTRACT

A series of 67 surgically treated spinal carcinomatous metastases is reviewed in order to establish the role played by surgery in the management of such a disease. The authors compare the results achieved in two groups of patients treated with a different therapeutic approach: either surgery alone or surgery associated with other therapies (mainly radiotherapy). On this basis, although no ideal treatment for spinal epidural metastases can be established, the authors suggest decompressive laminectomy as a first choice approach in the treatment of patients bearing a scarcely radiosensitive spinal metastasis with a rapidly deteriorating motor function.


Subject(s)
Spinal Neoplasms/secondary , Combined Modality Therapy , Humans , Male , Retrospective Studies , Spinal Neoplasms/diagnosis , Spinal Neoplasms/physiopathology , Spinal Neoplasms/surgery
SELECTION OF CITATIONS
SEARCH DETAIL
...